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SARCOPENIA is a hallmark of aging, occurs in multiple species, and its progression usually mirrors changes in 
body composition. Age-related changes in body composi-
tion have important clinical implications, given that the loss 
of muscle mass, gains in fat mass, and the consequent ram-
ifications on muscle strength may be independently associ-
ated with declining performance as well as increased risk 
for disability and mortality in older persons (1–4). In some 
experimental settings, behavioral interventions, such as 
moderate caloric restriction and physical exercise, have 
proven beneficial against age-associated changes in body 
composition and physical performance in targeted popula-
tions [eg, (5,6)]; however, very little is known regarding 
what benefit these interventions might have when initiated 
late in life. This is an extremely important empirical ques-
tion given that these behavioral interventions are not appro-
priate for all older adults (those not interested or are 
physically or cognitively incapable). The study of pharma-
cological mimetics of diet and exercise and the combination 
thereof may provide additional treatments for this vulnera-
ble population. Funding agencies are conducting late phase 
clinical trials, which study the impact of diet, exercise, and 
pharmacological interventions on the functional status of 
older individuals (7–9). Complementary preclinical studies 
represent an important translational link insofar as they may 
inform and guide the direction of and help in the interpreta-
tion of the results of these trials in terms of understanding 
the biological mechanisms of these treatments.
Incredible strides have been made over the last 70 years 
regarding our understanding of the basic biology of aging, 
which have provided the basis for the development of pre-
clinical models of late-life intervention strategies for com-
bating physical decline. The bulk of this work has been 
driven by the finding that a life-long reduction (40%) in 
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caloric intake prolongs life and reverses many cellular, mo-
lecular, and physiological changes, which occur with age, 
including increased inflammation, oxidative damage, and 
metabolic dysregulation, and reverses or attenuates the 
impact of sarcopenia (10–29). Although it is true that inter-
ventions that prolong life span seem to be correlated with 
increased physical function (30–32), it is not clear that the 
application of these interventions late in life will have the 
same effect. In fact there is very little evidence, clinically or 
preclinically, to suggest they will be effective. Furthermore, 
the biological changes that occur in the context of these 
interventions that relate to improvements in quality in mus-
cle function themselves may or not occur when initiated as 
late-life interventions.
With the continued “graying” of the worldwide population, 
the number of individuals at risk for developing physical dis-
ability continues to increase along with the social, emotional, 
and economic cost (33) of caring for such individuals, mandat-
ing the need for testing the effectiveness of health-promoting 
interventions within this cohort. We have focused on the use of 
a variety of late-life interventions designed to mitigate sarco-
penia and changes in body composition but have prioritized 
functional measures as our primary outcome. This is essential 
given that changes in physical function/activity are themselves 
observed across a wide variety of species and the primary out-
come of interest. Of course, this is not to the exclusion of the 
study of biological outcomes as the relationship between 
changes in behavior and biology is a major advantage and im-
perative for using preclinical models to further our under-
standing of human health. Furthermore, once the biological 
correlate or mechanisms of the behavior change of interest are 
identified, additional targets for alternative interventions such 
as pharmaceutical therapeutics may be revealed.
Therefore, in this review, we focus on those late-life in-
tervention studies from our laboratories, which directly as-
sess the relationship between physical function, sarcopenia, 
and body composition. We begin with providing a concep-
tual framework for the ever-changing definition of sarcope-
nia and a rationale for the use of an appropriate rodent 
model of this condition. We follow with a description of the 
evolution of these studies then finish by providing our per-
spective regarding the implications of this body of work and 
future areas of research that may also contribute to the ulti-
mate goal of maintaining functional independence in older 
individuals through extending their healthspan.
Sarcopenia Defined and Refined
The term “sarcopenia,” first coined by Rosenberg (34), is 
from the Greek meaning “poverty of flesh.” Sarcopenia has 
been referred to as a syndrome that includes not only the loss 
in muscle mass but also concomitant losses in muscle strength 
and poor physical function, although this has been debated 
recently (35,36). Nevertheless, the sequela of sarcopenia has 
been identified as a major cause underlying physical decline 
with age. Despite its importance, there is still much debate as 
to a universal set of criteria that defines the condition. In 
brief, most definitions have derived from epidemiological 
studies which present the issue in the context of clearly defin-
ing levels of muscle mass and/or indices of upper and lower 
extremity strength that predispose individuals to high risk of 
poor physical performance and disability (37–39). A major 
caveat to the approach is that one specific level is not neces-
sarily more predictive of changes in functional status than an-
other. This suggests that to demonstrate a relationship between 
sarcopenia and functional status, a more nuanced expansion 
of this definition is needed.
Emerging approaches to defining sarcopenia focus on 
both the strength and the muscle mass elements of the 
syndrome. For example, Clark and Manini (35,36) have 
coined the term “dynapenia” to refer to the age-related loss 
of strength, which cleverly translates from the Greek to 
“poverty of strength.” This is based on an analysis of the 
literature, demonstrating that (a) longitudinal aging studies 
indicate a dissociation between the loss of muscle mass and 
strength; (b) interventions such as growth hormone or tes-
tosterone supplementation, which clearly result in the hyper-
trophy of muscle, fail to provide the expected level of gains 
in strength; and (c) changes in muscle mass and changes in 
strength resulting from alterations in physical activity levels 
(ie, exercise training or disuse) do not follow the same time 
course. Instead, they suggest that rather than loss of mass per 
se, age-related alterations in biological systems afferent to or 
localized within the muscle undermine strength. This is not 
an entirely new perspective, but the conceptualization of dy-
napenia brings to the forefront the caveats involved in the 
classic definition of sarcopenia and draws attention away 
from establishing criteria for its diagnosis and treatment in 
terms of mass or strength in isolation. Finally, this concept 
highlights and gives priority to the importance of biological 
viability of the muscle tissue and upstream factors.
Of particular relevance to this review, is that the study of 
sarcopenia should also incorporate measures of overall 
body composition. In humans, there is a gradual increase in 
adiposity and loss of lean mass in both men and women 
from 25 to approximately 65 years of age, after which total 
body weight declines (40). As alluded to in the introduction, 
loss of muscle and gain of fat mass are independently as-
sociated with declining performance as well as increased 
risk for disability and mortality in older persons (1–4). 
Adipose tissue is a major endocrine organ, and far from its 
previously innocuous reputation as simply providing protec-
tion for internal organs, increased adiposity with age results 
in the convergence of several deleterious processes, including 
increased inflammation, insulin resistance, and oxidative 
stress. This situation may lead directly to accelerated loss of 
number and quality of myocytes (41), and each has been 
shown to correlate with declining physical performance 
and/or strength in both human and animal models (11,41–
51). In addition, with the increased overaccumulation of 
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abdominal fat, which is observed during aging (52,53), fat 
may also be ectopically deposited in nonadipose tissues, 
such as muscle, as the oxidative capacity of the adipose de-
pots is exceeded. This results in a lipotoxic environment 
such that an excess of fatty acids may feed into cytotoxic 
metabolic pathways such as de novo ceramide production 
and diacylglycerol deposition (54), both of which may lead 
to dysregulation of muscle function including cell death. 
Collectively, these data suggest that increased adiposity with 
age is an important determinant of both declining function 
and loss of muscle viability.
Although we have most likely duplicated information that 
is more extensively, and even more elegantly, reviewed else-
where in this special issue, we feel that this recapitulation 
is necessary for several reasons. First, in order to study 
sarcopenia, a conceptual biological framework, in this case, 
changes in muscle quality rather than muscle mass, is re-
quired to establish a point of intervention. Second, we iden-
tify a major contributor to sarcopenia, increased adiposity 
with age, in terms of its impact on declining function and 
dysregulation of skeletal muscle. Third, we would argue that 
because this increase in adiposity is associated with such a 
broad range of biological factors, one of the most critical 
outcomes in terms of evaluating the efficacy of interventions 
designed to ameliorate this rise in adiposity must relate to 
functional status. Finally, these data provide a rational inter-
section for translational studies which make use of animal 
models for establishing new and exciting interventions, for 
extending our knowledge of current interventions, and most 
importantly, to provide guidance in the design and interpre-
tation of both approaches when initiated late in life.
The Fischer 344 × Brown Norway Rat Is a Useful 
Preclinical Model for the Translational 
Study of Body Composition and Physical Decline
Choosing an animal model should be based solely on the 
hypothesis one is interested in addressing. Therefore, for 
several years, we have used the Fischer 344 × Brown Nor-
way (F344BN) rat as our model given the extensive body of 
published studies reported in this strain, regarding age- 
related changes in both behavioral function and skeletal 
muscle biology. Furthermore, there are many conceptual 
similarities between age-related changes observed in this 
strain and what is observed in humans. For example, several 
studies have shown that this strain proceeds from 80% to 
50% survival between 24 and 30 months of age (55). In hu-
mans, this same pattern of survival mirrors an exponential 
increase in disability (56). In fact, assessment of functional 
limitations in vicinity of the 50% survival range is highly 
predictive of mortality in both rats and humans. For example, 
we have previously reported that swimming speed perfor-
mance at 24 months of age predicts longevity in aged 
F344BN rats (Figure 1). This is particularly relevant in light 
of a recent paper by Studenski and colleagues (57–59) 
Figure 1. Least square means of the swimming speed procedures, over a 
6-month time period (24–30 months). Longevity was significantly predicted by 
higher baseline swim speed (hazard ratio 0.88 for 1 cm/s increase; 95% confi-
dence interval 0.81–0.97; p = .009),
advocating for the potential use of speed measurements for 
predicting disability. In the context of changing body compo-
sition, a similar association exists. In the F344BN, there is a 
gradual increase in both lean and fat mass through 24 months 
of age, a decrease in muscle and further increase in fat through 
27 months, and a decrease in both compartments thereafter 
(16,60,61). These changes in body composition mirror 
changes in cell signaling pathways in the skeletal muscle itself 
that are central to the viability and homeostasis of this tissue 
(inflammation, oxidative stress, insulin resistance, apoptosis, 
as examples and reviewed in detail elsewhere).
Therefore, in many of our experimental designs, we fo-
cus the initiation of interventions during this “critical win-
dow” during the life span. These studies are longitudinal in 
nature in that we follow the same animals over time in order 
to assess responses to treatment within individual subjects. 
We typically do not use young animals as controls because 
our hypotheses are designed to address whether functional 
performance may be improved by our late-life initiated 
treatments in older animals. The similarity between the 
F344BN rat strain and humans in terms of timing of late-life, 
age-related body composition changes, and declining perfor-
mance makes this strain an excellent model for studying the 
relationship between age, adiposity, muscle quality, and 
physical function. What follows is a conceptual rationale and 
example of our work in which we initiate pharmacological 
interventions, designed to mitigate age-related increases in 
adiposity, late in life with an eye toward ameliorating declin-
ing function. We also demonstrate a potential dissociation 
between interventions in terms of life span versus healthspan.
What Have We Learned From Preclinical 
Studies of Calorie Restriction and Exercise
Calorie Restriction
For decades, behavioral interventions, such as short-term 
moderate caloric restriction (CR) and physical exercise, have 
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proven beneficial against age-associated changes in body 
composition and physical performance in targeted popula-
tions; however, very little is known regarding what benefit 
these interventions may have when initiated late in life and 
for extended periods of time. This is especially critical 
given that NIH is currently sponsoring two large-scale clin-
ical trials to address both of these types of interventions in 
both younger and older individuals [see (8) for a description 
of the LIFE study and (7) for CALERIE]. Knowledge gar-
nered from preclinical studies may be especially informa-
tive in helping to guide these trials and interpret the resulting 
data.
From a functional perspective, it is well known that ro-
dents placed on a caloric restrictive diet across the life span 
show improved survival and a sparing of function in various 
motor performance tests including increased locomotor ac-
tivity (62,63). We have contributed to this literature by 
showing that the F344BN rat, with life-long CR (40%), ex-
hibit improved physical performance and that this effect is 
mediated by a decrease in adiposity and a lowering of in-
flammatory status. Certainly, very few people would advo-
cate the use of such severe forms of CR in older individuals, 
and controversy exists about the circumstances under which 
older adults should be advised to lose weight (64–67). Fur-
thermore, the second phase of the 2-year CALERIE trial of 
25% calorie restriction in nonobese individuals is currently 
underway; however, the target population is between ap-
proximately 20 and 50 years of age, which is well below the 
age of the large “baby boom” cohort for which interven-
tions are directly needed to curb an impending epidemic of 
functional decline.
Indeed, there has been no systematic study of the effects 
of CR when initiated late in life, using functional status as a 
primary outcome. However, Weindruch and colleagues (68) 
investigated the effects of varying degrees of CR on health 
and longevity in mice. They found that CR of all degrees 
tested, 25%, 55%, and 65% of the ad libitum diet, conferred 
improved health and longevity over ad libitum–fed control 
mice. It appears that the greater degree of CR, without in-
ducing malnutrition and starvation, the greater the effects 
on health and longevity of the mice. Although a lesser de-
gree of CR may not maximize the potential longevity ben-
efits, the potential healthspan benefits have not been 
extensively described. Restriction to a lesser degree is an 
intervention that is much more feasible for humans to main-
tain for the long term. In fact, Holloszy and colleagues (69) 
have shown that 8% CR increases mean life span without 
effecting maximal life span. The interpretation of these 
results was that 8% CR affects health-related outcomes 
without affecting a basic “aging” process. We have also 
shown that 8% CR reduces inflammatory status and im-
proves antioxidant production (50). Disease processes as 
well as the aging process are robustly associated with in-
creased adiposity and inflammatory status in a variety of 
species. Therefore, regimens such as 8% CR may positively 
impact declining physical performance by attenuating age-
related increases in inflammatory status, oxidative damage, 
and apoptosis in skeletal muscle (19,20,50,70). These data 
suggest that, in terms of preclinical studies, a more system-
atic study of varying “doses” of CR, initiated late in life 
may provide a translational link to help optimize the de-
sign of clinical studies for improving function in older 
individuals.
Exercise
Preclinical studies of life-long exercise interventions 
from our laboratory have focused on the use of wheel-run-
ning regimens pioneered by Holloszy and colleagues 
(28,71–74) as a model of voluntary exercise in Fischer 344 
(F344) rats. This is usually accompanied by a slight reduc-
tion in caloric intake (8%) in order to keep animals in a 
heightened state of motivation to ensure they will maintain 
wheel running. This situation results in a reduction in adi-
posity and a preservation of a variety of indices of skeletal 
muscle function. We have extended this line of research by 
investigating late-life initiation of voluntary wheel running 
without accompanied CR in aged F344BN rats (Figure 2). 
Voluntary wheel running in aged rats significantly reduced 
adiposity and body weight, although these rats engaged in 
very low levels of wheel running (as few as nine revolutions 
per day). The body weight loss was accompanied by an in-
crease in physical performance (75). Although these data 
show that aged F344BN rats are relatively inactive, a very 
small amount of increase in physical activity is beneficial to 
physical performance. The impact on muscle quality is un-
known.
With forced exercise, our studies demonstrated that rela-
tively high-intensity (25 cm/s, 30 minutes, 5 d/wk) short-
term training (4 weeks) in 28-month-old male F344BN rats 
improves exercise capacity and physical performance (76). 
In addition, we detected an age-related increase in a variety 
of markers of apoptosis and apoptotic DNA fragmentation in 
the extensor digitorum longus muscle of old sedentary rats, 
which was attenuated/reversed by exercise. We have also 
collected very preliminary data monitoring changes in body 
weight and exercise tolerance in aged F344BN male rats af-
ter 4 weeks of low-intensity (12 cm/s, 10 min/d, 5 d/wk) 
treadmill exercise alone or combined with enalapril treat-
ment. Indeed, the combination of enalapril + exercise main-
tained exercise tolerance and decreased weight gain relative 
to exercise alone. Therefore, it is quite likely that longer-
term treadmill exercise in this strain of rat may also reduce 
adiposity and, hence, reverse the increased inflammation 
that leads directly to apoptosis, attenuate the loss of muscle 
mass, and ultimately protect against declining physical per-
formance. Moreover, exploration of low-intensity exercise 
in combination with various adjuvant pharmacological ther-
apies may provide a benefit to those aged individuals who 
may experience difficulty in exercising (see subsequently).
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Some controversy does exist regarding the impact of the 
potentially stressful nature of forced exercise. Indeed, life-
long intense treadmill exercise may have adverse conse-
quences (77,78); however, a recent study by Betik and 
colleagues (79) demonstrated that 5 or 7 months of tread-
mill exercise training initiated in 29-month-old F344BN 
rats resulted in greater exercise capacity during an incre-
mental treadmill exercise test and reduced percent body fat. 
Quite interestingly, this increase in functional performance 
was observed in the absence of increased muscle aerobic 
capacity, muscle mass, and other markers of mitochondrial 
function highlighting the importance of using behavioral 
outcomes as a measure of the success of a particular inter-
vention. Together, these data suggest that late-life initiation 
of exercise improves physical function in the context of a 
reduction in adiposity and preservation of some aspects of 
muscle quality. Moreover, in the case with voluntary wheel 
running, very little exercise is necessary to achieve beneficial 
outcomes.
Pharmacological Intervention: CR Mimetics
Pharmacological approaches may be particularly relevant 
late in life because not all older individuals benefit from or 
are capable of participating in traditional diet and/or exer-
cise programs (eg, those that are obese, frail, or arthritic). 
This notion has benefited from an evolving area of research 
focused on the application of CR “mimetics” (80) which tar-
get cell signaling pathways that may be involved in the basic 
biology of aging. The National Institute on Aging is on the 
forefront of this movement and has spearheaded the devel-
opment of an interventions testing program to investigate 
CR mimetics across three different institutes in genetically 
diverse mice (80). The objective of the program is to de-
velop interventions that produce the same prolongevity 
effects that CR provides but without reducing caloric intake 
or inhibiting food intake. However, this does not preclude 
the notion that such mimetics may still affect differential 
Figure 2. Latency to fall (a) from an incline plane in 24-month-old F344BN male rats that were wheel running for 2 weeks (n = 20) or were sedentary (n = 19). 
*p = .04 for difference from a wheel-running group by t test. (b) Correlation between latency to fall from an incline plane and body weight, p = .037, r2 = .112.
regulation of adiposity. Independent investigators were en-
couraged to “sponsor” compounds with adequate rationale. 
Most importantly, due to experimental caveats, the adminis-
tration of many of these compounds began at 20 months of 
age, thereby creating an experimental situation of late-life 
administration of prolongevity pharmacological interventions.
Our interest was piqued given that we and others have 
previously shown that physical function is predictive of lon-
gevity (albeit over a compressed period of time) and that 
life-long CR improves function (30). Therefore, a major 
empirical question is whether or not CR mimetics that pur-
port to increase life span necessarily translate into mimetics 
of increased functional performance. Here, we highlight re-
sults of our tests on physical function/activity and adiposity 
in the F344BN rat using two compounds used in the inter-
ventions testing program and recently reported on (81): one 
which extended life span (rapamycin) and another which 
our group proposed (enalapril) that did not extend life span. 
We show that using both treatments, regardless of the im-
pact on longevity observed in interventions testing program 
mice, resulted in decreased adiposity/weight loss and improved 
functional/activity outcomes.
Rapamycin
To be sure, some of the most promising data to emerge 
from the interventions testing program are related to the use 
of the compound rapamycin (81). This compound was ac-
cidentally discovered in the soil of the island of Rapa Nui 
(hence its name) and was found to have powerful antifungal 
properties. Since that time, the compound has been used as 
a therapy for organ rejection in kidney transplantation and is 
currently in trials for cancer treatment. Rapamycin inhibits 
the TOR (target of rapamycin) pathway, which is central to 
the regulation of nutrient sensing, cell survival/death, pro-
tein synthesis, and many other metabolic processes. 
Although inhibition of the TOR pathway by genetic or 
pharmacological means has been shown to extend life span 
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Figure 3. Young and old F344BN rats were fed rapamycin for 3 weeks or were given a regimen of intermittent (every other day) calorie restriction (IF). IF- and 
rapamycin-treated animals lost approximately 15% of their body weight relative to controls. Moreover, the young IF animals lost more weight than their rapamycin-
fed counterparts (lower panel). There was an effect of age on the memory test (upper right); however, rapamycin had no impact on cognitive function, although 
physical activity was increased with treatment, regardless of age (*all ps < .05).
in invertebrates, the effect in mammals was not known. As 
stated above, when rapamycin was fed to male and female 
mice beginning at 600 days of age, it led to an increase in 
life span of 14% for females and 9% for males. A subse-
quent study initiated at 270 days of age has also been show 
to increase survival in both male and female mice, based on 
an interim analysis conducted near the median survival 
point. The real strength of these data is threefold because 
the life-span enhancing effect of rapamycin is (a) observed 
in both males and females, (b) observed when initiated very 
late in life, and (c) highly replicable given that it was 
observed at three separate institutions.
We have conducted a preliminary study (C. Leeuwenburgh, 
T. C. Foster, C.S. Carter, unpublished data, 2009) (Figure 3) 
in our laboratory using the F344BN rat to investigate whether 
rapamycin ameliorates age-related weight loss, cognitive 
function, and activity levels. In this case, young and old 
F344BN rats were fed rapamycin for 3 weeks or were given 
a regimen of intermittent (every other day) calorie restriction 
(IF). Body weight and food intake were monitored on a daily 
basis. After 3 weeks, we assessed memory using the object 
recognition paradigm in which an animal recognizes a novel 
object when presented along with a variety of other objects, 
which have been presented 24 hours previously. “Recognition” 
is measured by the amount of time the animal spends explor-
ing the novel object. All IF- and rapamycin-treated animals 
lost approximately 15% of their body weight relative to con-
trols. Moreover, the young IF animals lost more weight than 
their rapamycin-fed counterparts. This was correlated with 
feeding patterns. Young and old IF as well as old rapamycin-
treated animals reduced their food intake by 20–30%, 
whereas the young rapamycin-treated animals reduced in-
take by less than 10%. Finally, neither rapamycin nor IF 
feeding had any impact on cognitive function, although 
physical activity was increased in both treatment groups, 
regardless of age. Indeed, we and others have emphasized 
that tasks which involve exploration as a component of the 
outcome variable (in this case, time spent exploring 
objects) may be subject to the confound that movement and 
activity are influenced by motivational state (in this case, 
food restriction). Further study is warranted to assess 
whether longer-term treatment yields similar results or if 
the nature of weight loss observed is selective to a particu-
lar body compartment (fat vs lean) and related to physical 
function.
Elsewhere in the literature, rapamycin’s role in modulating 
adiposity and skeletal muscle metabolic activity have re-
sulted in paradoxical conclusions. For example, Houde and 
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colleagues (82) have shown that rapamycin administered to 
young rats for 15 days reduced adiposity and fat cell num-
ber and was associated with a coordinated down regulation 
of genes involved in both lipid uptake and output. However, 
insulin resistance, severe glucose intolerance, and increased 
gluconeogenesis were also observed. Similarly, Chang and 
colleagues (83) have demonstrated that obese KK/HlJ mice 
treated with rapamycin for 42 days, while on a high-fat diet, 
lost body weight and adiposity also had higher serum insu-
lin levels and food intake. This resulted in marked decline in 
glucose tolerance paralleled by increased generation of 
plasma reactive oxygen species. These findings suggest that 
rapamycin administration may help to prevent diet-induced 
obesity, whereas prolonged use of rapamycin may exacer-
bate glucose intolerance. Furthermore, mTOR (the mam-
malian target of rapamycin) is known to decrease with age 
in F344BN rat skeletal muscle and is highly correlated with 
atrophy (84). However (85), translational signaling of 
mTOR in young adult and aged plantaris muscle is equally 
responsive to chronic overload after bilateral synergist abla-
tion. These data suggest that while down regulation of 
mTOR may be beneficial for overall longevity, aged muscle 
and the susceptibility to insulin resistance requires adequate 
levels of mTOR functioning. In addition, aging skeletal 
muscle may respond adaptively, perhaps via mTOR signal-
ing to interventions such as exercise protocols, which serve 
to load muscle.
Enalapril
Enalapril is an angiotensin-converting enzyme inhibitor, 
whose primary use is for the control of hypertension. However, 
beyond its impact on hemodynamic functioning, enalapril 
has been shown to modulate an amalgam of biological pro-
cesses inherent to overall metabolic function, such as insu-
lin sensitivity, inflammation, and oxidative resistance (86). 
In addition, observational studies in humans and converging 
evidence from our laboratory suggest that the use of angio-
tensin-converting enzyme inhibitors attenuate age-related 
increases in whole-body adiposity and physical perfor-
mance decline, in the absence of any sizeable muscle hyper-
trophic effect (60,87–90). We observed no difference in a 
variety of physiological endpoints which may themselves 
cause a reduction in body weight (food intake, temperature, 
glucose and insulin levels, pathology) and which may be 
secondary to the effects of enalapril. This benefit is not iso-
lated to skeletal muscle in that recently we (91) and others 
have shown that enalapril treatment mitigates dysfunction 
in other organ systems, including kidney and heart, which 
appear to be mediated through reductions in oxidative 
stress, inflammation, and insulin signaling (92–101). Since 
then, several other studies have demonstrated similar effects 
of angiotensin-converting enzyme inhibitors, in particular 
enalapril, on body composition in various strains of rats and 
mice, across different ages, and under normal and high-fat 
feeding scenarios (102,103). Indeed, these data lend cre-
dence to the hypothesis that it is not necessary to optimize 
the quantity of muscle that is preserved with an intervention 
but that it is the quality of muscle that remains which deter-
mines functionality. In order to expand our understanding 
of how this decrease in adiposity may play a role in preserv-
ing skeletal muscle quality, we used gene array technology 
to identify potential cell signaling pathways that are altered 
with enalapril and showed that mitochondria-mediated 
apoptosis is mitigated with this treatment (104). Finally, a 
very novel finding of this body of work was that the weight 
loss observed was also not due to some unobservable patho-
logical catabolic state, and in fact, quite the opposite oc-
curred in that enalapril attenuated the age-related increase 
in spontaneous tumor development relative to placebo-
treated animals.
Figure 4. Four weeks of low-intensity exercise (12 cm/s; 10 combined with low-dose enalapril treatment (20 mg/kg/d) administered to 24-month-old male 
F344BN rats results in additional weight loss and greater endurance relative to enalapril treatment alone (*p < .05).
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Taken together, these data suggest that while rapamycin 
is a promising life-span compound, caution should be taken 
in generalizing this impact in terms extending healthspan 
due to the negative impact of mTOR blockade on skeletal 
muscle function and the development of overt insulin resis-
tance. In contrast, with enalapril, no life-span enhancement 
was observed, although we did observe improvements in 
whole-body adiposity, muscle quality, and physical perfor-
mance. These data suggest that there is dissociation between 
the potential life-span and healthspan effects of treatments, 
which purport to mimic caloric restriction and that alternative 
approaches should be considered to maximize both.
Conclusions
There are key components explicated in this review that 
we believe that would help to define a new perspective in 
developing preclinical late-life intervention strategies that 
may have translational value in combating declining func-
tion in older individuals. These include (a) choosing a 
proper preclinical model in terms of identifying a time 
frame for a late-life intervention, (b) applying a clear work-
ing definition of sarcopenia, (c) assessing a mixture of both 
functional and biological outcomes, (d) carefully consider-
ing the choice of the intervention, and (e) highlighting the 
translation of findings to clinical studies.
For the most part, the data presented in this review are 
heavily biased toward the F344BN rat model because it has 
the qualities necessary to address our hypotheses. Of course, 
this does not mean that other types of animal models are less 
important. To be sure, the development and ultimate strength 
of any scientific set of hypotheses must rely on converging 
evidence from multiple sources including other strains and 
species, and genetically altered models. However, in terms 
of behavior and physiology, the F344BN is an excellent 
choice for evaluating changes in physical function.
The assessment of behavioral outcomes is essential to 
measuring the efficacy of any late-life intervention in the 
context of mitigating declining performance. In a recent re-
view, a set of criteria were suggested for assessing the suc-
cess of any late-life intervention; the primary outcome was 
stated as slowing healthspan decline, and consisted of the 
classic set of biomarkers (inflammation, oxidative stress, 
insulin function, etc.) (105). However, functional/behav-
ioral markers were not mentioned. Studies in humans re-
garding the nature of the definition of sarcopenia all agree 
that improved physical functioning is the major determinant 
of whether an intervention is successful given that measures 
of muscle strength and mass are often uncorrelated or do 
not predict this outcome. In addition, interventions may 
have ubiquitous effects, each of which may be separately or 
wholly uncorrelated with their functional counterparts. 
Furthermore, like any good biomarker, behavior may be 
considered both a predictor and an outcome measure of 
response to treatment.
Finally, we should not be dismissive of pharmacological 
compounds that do not extend life span at the risk of over-
looking potential therapeutics for enhancing healthspan. 
There may in fact be overt dissociations between the two 
such that life span may be enhanced at the expense of overall 
function. This is especially relevant to assessing late-life 
interventions, for which there is a growing need in the con-
text of the world’s rapidly aging population and for which 
very little clinical data exist. Indeed, healthspan-enhancing 
therapeutics may create synergy when partnered with be-
havioral approaches such as mild levels of CR or low levels 
of exercise/physical activity and may be most effective in 
those vulnerable aged populations (obese, frail, arthritic, 
etc.) which are most challenged to engage in exercise/
physical activity or for whom excessive weight loss is not 
recommended. By way of example, we have demonstrated 
that short-term very low-intensity exercise combined with 
low-dose enalapril treatment results in greater exercise 
tolerance compared with exercise alone in aged F344BN 
rats (C. S. Carter, K. Sweet, A. Posgai, E. Marzetti, unpub-
lished data, 2010) (Figure 4). The converse may also be 
true, such that exercise or CR or pharmacological inter-
ventions may perhaps confer no benefit to function and 
perhaps may even cause harm. Preclinical models, espe-
cially those for which function is a primary outcome, rep-
resent a critical translational link for the more rapid 
translation of treatments to the clinical arena insofar as 
they may serve as a tool for the relatively rapid systematic 
assessment of traditional and nontraditional interventions, 
initiated late in life.
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